Securian Asset Management Inc. Sells 107 Shares of Repligen Co. (NASDAQ:RGEN)

Securian Asset Management Inc. lowered its stake in Repligen Co. (NASDAQ:RGEN) by 2.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 3,937 shares of the biotechnology company’s stock after selling 107 shares during the period. Securian Asset Management Inc.’s holdings in Repligen were worth $567,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of RGEN. Resources Management Corp CT ADV bought a new stake in Repligen in the third quarter valued at approximately $37,000. Quarry LP lifted its position in Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 239 shares during the last quarter. UMB Bank n.a. lifted its position in Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 110 shares during the last quarter. Global Retirement Partners LLC lifted its position in Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 129 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in Repligen by 15.2% in the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 90 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

RGEN has been the subject of several recent research reports. StockNews.com downgraded Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. Royal Bank of Canada upped their target price on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. TD Cowen assumed coverage on Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 target price for the company. Finally, JPMorgan Chase & Co. upped their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $181.00.

Repligen Price Performance

Shares of RGEN stock opened at $150.62 on Monday. The stock has a market cap of $8.44 billion, a price-to-earnings ratio of -295.33, a PEG ratio of 4.54 and a beta of 0.95. The business’s fifty day moving average is $157.19 and its 200 day moving average is $148.52. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $200.23. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Research analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.